Wadasaki Koichi, Matsuura Kanji, Murakami Yuji, Kenjo Masahiro, Kaneyasu Yuko, Fujita Minoru, Ito Katsuhide, Tatsukawa Ryuji, Takeno Yukio, Hirakawa Katsuhiro
Department of Radiology, Graduate School of Biomedical Sciences, Hiroshima University.
Gan To Kagaku Ryoho. 2007 Sep;34(9):1393-6.
Twenty-eight patients with oropharyngeal or hypopharyngeal carcinoma received concurrent chemoradiotherapy with CDDP or CDGP plus 5-FU between January 2001 and April 2006. The numbers of patients according to clinical stage were stage II:2; stage III:5; stage IVa:19 ; and stage IVb:2. Total radiation dose was 60-73.8 Gy (median 66 Gy) and overall treatment time was 41-57 days (median 47 days). Two courses of 5-FU 700 mg/m(2) on days 1-5 and CDDP or CDGP 70 mg/m(2) on day 4 were administered concurrently with radiotherapy. Median follow-up period was 26 months (range, 8-64 months). The incidences of grade 3 or greater acute toxicity were leukopenia 29%, anemia 21%, thrombocytopenia 7%, pharyngeal mucositis 43% and nausea 14%. No severe late toxicity was observed. Treatment responses of primary lesions were CR in 24 patients (86%) and PR in 4 patients (14%). The two-year local control rate was 87% and the 2-year overall survival rate was 72%. Concurrent chemoradiotherapy with CDDP or CDGP plus 5-FU seemed to be effective for advanced carcinomas of the oropharynx and hypopharynx.
2001年1月至2006年4月期间，28例口咽或下咽癌患者接受了顺铂或奈达铂联合5-氟尿嘧啶的同步放化疗。根据临床分期，患者数量分别为：II期2例；III期5例；IVa期19例；IVb期2例。总辐射剂量为60-73.8 Gy（中位值66 Gy），总治疗时间为41-57天（中位值47天）。在放疗的同时，于第1-5天给予两疗程的5-氟尿嘧啶700 mg/m²，第4天给予顺铂或奈达铂70 mg/m²。中位随访期为26个月（范围8-64个月）。3级及以上急性毒性的发生率分别为：白细胞减少29%、贫血21%、血小板减少7%、咽黏膜炎43%、恶心14%。未观察到严重的晚期毒性。原发灶的治疗反应为完全缓解（CR）24例（86%），部分缓解（PR）4例（14%）。两年局部控制率为87%，两年总生存率为72%。顺铂或奈达铂联合5-氟尿嘧啶同步放化疗似乎对晚期口咽和下咽癌有效。
